Top Markets
Coin of the day
Medicus Pharma Ltd. Common Stock Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd. Common Stock

MDCX
Rank in Stocks #33833
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated... Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Share Price
$0.3079
Last synced: 2026-08-14
Market Cap
$6.79M
Change (1 day)
-13.02%
Change (1 year)
-84.29%
Country
CA
Trade Medicus Pharma Ltd. Common Stock (MDCX)

Category

P/E ratio for Medicus Pharma Ltd. Common Stock (MDCX)
P/E ratio as of 2026 TTM: 0
According to Medicus Pharma Ltd. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Medicus Pharma Ltd. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -
US
30.62 -
NL
- -
CH
- -
KR
18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.